Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

[Rotavirus vaccination in 2012. Position of the Pediatric Infections Pathology Group (GPIP) and the French Association of Ambulatory Pediatrics (AFPA)].

Dommergues MA, Gaudelus J, Weil-Olivier C, Thiebault G, Vié le Sage F, Virey B, Dufour V, Romain O, Cohen R; Groupe de Pathologie Infectieuse Pédiatrique.; Association Française de Pédiatrie Ambulatoire..

Arch Pediatr. 2012 Nov;19 Suppl 3:S150-7. doi: 10.1016/S0929-693X(12)71290-3. French.

PMID:
23178138
2.

[Plea for advancement of the age of vaccination against human papillomavirus in France: Position of the Pediatric Infections Pathology Group (GPIP) and the French Association of Ambulatory Pediatrics (AFPA)].

Cohen R, Vié Le Sage F, Weil-Olivier C, Romain O, Hau I, Guérin N, Thiebault G, Virey B, Bakhache P, Dommergues MA, Gaudelus J; Commission Vaccin du Groupe de Pathologie Infectieuse Pédiatrique.; Association Française de Pédiatrie Ambulatoire..

Arch Pediatr. 2012 Nov;19 Suppl 3:S145-9. doi: 10.1016/S0929-693X(12)71289-7. French.

PMID:
23178137
3.

[Rotavirus vaccination in France: recommendations of the French Speaking Group of Pediatric Gastroenterology, Hepatology and Nutrition].

Olives JP, Tounian P, Lamireau T; Groupe Francophone d'Hepatologie, Gastroenterologie et Nutrition Pediatriques..

Arch Pediatr. 2007 Oct;14 Suppl 3:S194-6. French.

PMID:
17961815
4.

Rotavirus vaccines: targeting the developing world.

Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S160-6.

PMID:
16088799
5.

Rotavirus vaccines and vaccination in Latin America.

Linhares AC, Bresee JS.

Rev Panam Salud Publica. 2000 Nov;8(5):305-31. Review.

PMID:
11190969
6.

Implementing rotavirus vaccination in Asia.

Santosham M, Nelson EA, Bresee JS.

Vaccine. 2007 Nov 1;25(44):7711-6. Epub 2007 Aug 22.

PMID:
17881099
7.

Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Plosker GL.

Pharmacoeconomics. 2011 Nov;29(11):989-1009. doi: 10.2165/11207210-000000000-00000. Review.

PMID:
21988293
8.

Outstanding challenges for rotavirus vaccine introduction in low-income countries--a systematic review.

Ustrup M, Madsen LB, Bygbjerg IC, Konradsen F.

Dan Med Bull. 2011 Oct;58(10):A4323. Review.

PMID:
21975154
9.

Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease.

Gleizes O, Desselberger U, Tatochenko V, Rodrigo C, Salman N, Mezner Z, Giaquinto C, Grimprel E.

Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S12-21. Review.

PMID:
16397425
10.

Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Grimwood K, Lambert SB, Milne RJ.

Paediatr Drugs. 2010 Aug 1;12(4):235-56. doi: 10.2165/11537200-000000000-00000. Review.

PMID:
20593908
11.

Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.

Patel MM, Parashar UD.

J Infect Dis. 2009 Nov 1;200 Suppl 1:S291-9. doi: 10.1086/605059. Review.

PMID:
19817612
12.

Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.

Rheingans R, Atherly D, Anderson J.

Vaccine. 2012 Apr 27;30 Suppl 1:A15-23. doi: 10.1016/j.vaccine.2012.01.018.

PMID:
22520124
13.

Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception.

Patel MM, Clark AD, Glass RI, Greenberg H, Tate J, Santosham M, Sanderson CF, Steele D, Cortese M, Parashar UD.

Vaccine. 2009 May 14;27(22):2916-22. doi: 10.1016/j.vaccine.2009.03.016. Epub 2009 Mar 25.

PMID:
19428901
14.

Effects of vaccine on rotavirus disease in the pediatric population.

Dennehy PH.

Curr Opin Pediatr. 2012 Feb;24(1):76-84. doi: 10.1097/MOP.0b013e32834ee594. Review.

PMID:
22189398
15.

Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.

Atherly DE, Lewis KD, Tate J, Parashar UD, Rheingans RD.

Vaccine. 2012 Apr 27;30 Suppl 1:A7-14. doi: 10.1016/j.vaccine.2011.12.096.

PMID:
22520139
16.

Epidemiology and prevention of rotavirus infection: an underestimated issue?

Meloni A, Locci D, Frau G, Masia G, Nurchi AM, Coppola RC.

J Matern Fetal Neonatal Med. 2011 Oct;24 Suppl 2:48-51. doi: 10.3109/14767058.2011.601920. Review.

PMID:
21749188
17.

Rotavirus vaccines in developing countries: the potential impact, implementation challenges, and remaining questions.

Cherian T, Wang S, Mantel C.

Vaccine. 2012 Apr 27;30 Suppl 1:A3-6. doi: 10.1016/j.vaccine.2011.10.007. Review.

PMID:
22520133
18.

Physicians' knowledge and attitudes about rotavirus gastroenteritis and rotavirus vaccine.

Haupt RM, Isikci O, Kimble WL, Sotos GL, Fu J.

Pediatr Ann. 2006 Jan;35(1):54-61.

PMID:
16466076
19.

Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.

Standaert B, Parez N, Tehard B, Colin X, Detournay B.

Appl Health Econ Health Policy. 2008;6(4):199-216. doi: 10.2165/00148365-200806040-00003.

PMID:
19382820
20.

Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries.

Giaquinto C, Dominiak-Felden G, Van Damme P, Myint TT, Maldonado YA, Spoulou V, Mast TC, Staat MA.

Hum Vaccin. 2011 Jul;7(7):734-48. doi: 10.4161/hv.7.7.15511. Epub 2011 Jul 1. Review.

PMID:
21734466

Supplemental Content

Support Center